Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A ¥21.20, price ¥15.45, upside +37.2%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Wuhan Easy Diagnosis Biomedicine Co Ltd Class A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥13.85 – ¥46.74 · fair‑value band ¥10.29 – ¥33.26 · the ¥15.45 price screens below the ¥21.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Wuhan Easy Diagnosis Biomedicine Co Ltd Class A in your weekly email
Every Wednesday you see whether Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services.
Show more
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware products. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Stock analysis
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) currently trades at ¥15.45, while our model-based Fair Value estimate is ¥21.20, implying the stock looks roughly 27.1% undervalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ¥17.12 per share, and 3 of the 3 models we run sit above the ¥15.45 price.
Bear case: the Asset-Based group reads lowest at ¥15.93, and 0 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥10.29 (bear) to ¥33.26 (bull), the price of ¥15.45 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A reported revenue of 265M CNY in FY2025 versus 2.8B CNY in FY2021, a compound −44.7%/yr. Reported net income was −16.5M CNY in FY2025.
Key figures
Market cap 3.6B CNY (≈ $536M) · P/S ratio 13.1 · EPS (TTM) ¥−0.0500 · Dividend yield 7.5% · Net margin −6.2% · Return on equity −1.2% · Return on assets (EBIT) 21.2% · Operating margin −18.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 37%, 002932 screens cheaper than that median.
Fair Value models
Bear ¥10.29Fair Value ¥21.20Bull ¥33.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−24.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−70.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.7%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
58.6% (2020) → −40.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Wuhan Easy Diagnosis Biomedicine Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 358 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside+37% · Top 25%
Profitability
Return on assets−2% · Below median
Net margin (TTM)−5% · Below median
Operating margin (TTM)−18% · Bottom 25%
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)7.5% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/002932
Frequently asked questions
Is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥21.20 versus a price of ¥15.45, about +37% upside (undervalued).
What is the fair value of 002932?
Our model-based fair value for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is ¥21.20 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥15.45.
What is the quality score of 002932?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Our model-based price target is the fair value of ¥21.20 (as of Sep 23, 2026) from 3 valuation models. Cautious scenario ¥10.29, optimistic scenario ¥33.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock forecast for 2026?
Our models put fair value at ¥21.20, about +37% upside versus a price of ¥15.45 (undervalued). Cautious scenario ¥10.29, optimistic scenario ¥33.26. The calculation is refreshed regularly with new filings.
What is the revenue of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A reported trailing-twelve-month revenue of about 266M CNY (latest available figure, as of Sep 23, 2026).
Does Wuhan Easy Diagnosis Biomedicine Co Ltd Class A pay a dividend?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A currently shows a dividend yield of about 7.55% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan Easy Diagnosis Biomedicine Co Ltd Class A it is ¥21.20 per share (as of Sep 23, 2026), against a price of ¥15.45. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 002932 trades below its calculated fair value: price ¥15.45, fair value ¥21.20, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002932?
No. The price is what the market pays today (¥15.45); the fair value is what the company's own numbers justify (¥21.20). For Wuhan Easy Diagnosis Biomedicine Co Ltd Class A the two are ¥5.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A worth?
The market values Wuhan Easy Diagnosis Biomedicine Co Ltd Class A at about 3.6B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥15.45; our models calculate a fair value of ¥21.20 per share.
What do the bullish and bearish scenarios say about 002932?
Our models span a range for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A: cautious scenario ¥10.29, base ¥21.20, optimistic ¥33.26 per share (as of Sep 23, 2026, price ¥15.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Balance-sheet figures for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (as of Sep 23, 2026): return on equity −1.2%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 002932 from its 52-week high?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A trades at ¥15.45, about 25% below its 52-week high of ¥20.47 and 12% above the low of ¥13.85 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥21.20 is for.
Which stocks are comparable to Wuhan Easy Diagnosis Biomedicine Co Ltd Class A?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock attractive at the current price?
The data as of Sep 23, 2026: price ¥15.45, calculated fair value ¥21.20 (+37%), Quality Score 42/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002932 calculated?
We run Wuhan Easy Diagnosis Biomedicine Co Ltd Class A through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥21.20, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Wuhan Easy Diagnosis Biomedicine Co Ltd Class A currently trades 37 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The closing price on Sep 22, 2026 was ¥15.45. Our model-based fair value is ¥21.20, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan Easy Diagnosis Biomedicine Co Ltd Class A right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide (¥10.29 to ¥33.26). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) come from?
Earnings per share at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A grew +48.4 % a year from 2013 to 2024. Broken into its drivers: revenue per share +47.7 %, EBIT margin +1.4 %, tax rate −0.1 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
How large is the market capitalisation of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The market capitalisation of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 3.6B CNY (≈ $536M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The price-to-sales ratio of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 13.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Earnings per share at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A are ¥−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The dividend yield of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 7.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The net margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −6.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The return on equity (ROE) of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
On an EBIT basis the return on assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 21.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The operating margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −18.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Revenue at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is growing +1.0% versus a year earlier (3y avg −70.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Earnings per share at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A are growing −93.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) generate?
The free cash flow of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −161M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) hold?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A holds more cash than debt, 485M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Wuhan Easy Diagnosis Biomedicine Co Ltd Class A in the live analysis
One click puts Wuhan Easy Diagnosis Biomedicine Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
